The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma

Molecular Imaging and Biology

Volumn 6, Issue 4, 2004, Pages 200-207

  Macapinlac, Homer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

FDG; Lymphoma; Melanoma; PET

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GALLIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BRAIN LYMPHOMA; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHOMA; MEDICAL ASSESSMENT; MELANOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PATIENT MONITORING; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOLOGIST; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

EID: 3543116692     PISSN: 15361632     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mibio.2004.04.002     Document Type: Article

References (19)

1. Newman J.S. Francis I.R. Kaminski M.S. et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT Radiology 190 1994 111-116
2. Gritters L.S. Francis I.R. Zasadny K.R. et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma J. Nucl. Med. 34 1993 1420-1427
3. Shipp M.A. Harrington D.R. Anderson J.R. et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project N. Engl. J. Med. 329 1993 987-994
4. Young C.S. Young B.L. Smith S.M. Staging Hodgkin's disease with 18-FDG-PET: comparison with CT and surgery Clin. Pos. Imag. 1 1998 161-164
5. Bangerter M. Kotzerke J. Griesshammer M. et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest Acta Oncol. 38 1999 799-804
6. Roelcke U. Leenders K.L. Positron emission tomography in patients with primary CNS lymphomas J. Neurooncol. 43 1999 231-236
7. Bangerter M. Moog F. Griesshammer M. et al. Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment Radiography 5 1999 155-163
8. Cremerius U. Fabry U. Neuerburg J. et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma Nucl. Med. Commun. 19 1998 1055-1063
9. Naumann R. Vaic A. Beuthien-Baumann B. et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma Br. J. Haematol. 115 2001 793-800
10. Spaepen K. Stroobants S. Dupont P. et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J. Clin. Oncol. 19 2001 414-419
11. Spaepen K. Stroobants S. Dupont P. et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann. Oncol. 13 2002 1356-1363
12. Wirth A. Seymour J.F. Hicks R.J. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma Am. J. Med. 112 2002 262-268
13. Balch C.M. Buzaid A.C. Soong S.-J. et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J. Clin. Oncol. 19 2001 3635-3648
14. Morton D.L. Thompson J.F. Essner R. et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group Ann. Surg. 230 1999 453-463 discussion 463-465
15. 18F-fluorodeoxyglucose positron emission tomography. Results of a prospective trial of 100 patients Cancer 82 1998 1664-1671
16. Crippa F. Leutner M. Belli F. et al. Which kinds of lymph node metastases can FDG-PET detect? A clinical study in melanoma J. Nucl. Med. 41 2000 1491-1494
17. Mijnhout G.S. Hoekstra O.S. van Lingen A. et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma J. Clin. Pathol. 56 2003 283-286
18. Gulec S.A. Faries M.B. Lee C.C. et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making Clin. Nucl. Med. 28 2003 961-965
19. Schoder H. Larson S.M. Yeung H.W. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies J. Nucl. Med. 45 Suppl 1 2004 72S-81S